# **PHARMACY CORNER**

### Initial Therapy Use Granted to Dasatinib for Certain Leukemias



Dasatinib (Sprycel®, Bristol Myers Squibb) has now received accelerated U.S. Food and Drug Administration (FDA) approval as an

initial therapy in treating Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CP-CML). The drug had previously been approved for CP-CML in patients demonstrating resistance or intolerance to imatanib (Gleevec<sup>®</sup>, Novartis Pharmaceuticals).

Accelerated approval was granted based on data reported to the FDA from a study of 519 patients with newly diagnosed CP-CML randomized to receive dasatinib 100 mg daily (n = 259) or imatinib 400 mg daily (n = 260). Confirmed complete cytogenic response within 12 months on two consecutive occasions at least 28 days apart was achieved by 77% of dasatinib users and 66% of imatinib users (p = 0.007).

Dasatinib is a multikinase inhibiting oral agent and is dosed at 100 mg daily to treat CP-CML. Adverse reactions that nurses should monitor for include myelosuppression, bleeding events related to thrombocytopenia, fluid retention, QT prolongation, and cardiac dysfunction, including congestive heart failure. Women should be educated about pregnancy prevention secondary to teratogenic effects.

For patients receiving proton-pump inhibitors, changing to an antacid should be considered because proton-pump inhibitors may decrease dasatinib levels. Antacids should not be given within two hours of dasatinib because they could decrease dasatinib levels. Dasatinib is metabolized via the CYP3A4 pathway, and dosages may have to be adjusted if other strong CYP3A4 inhibitors or inducers cannot be avoided. Dasatinib should not be crushed or broken. It can be taken with meals; however, grapefruit juice should be avoided because it could lead to increased drug levels.

For more information, visit www.fda .gov/AboutFDA/CentersOffices/CDER/ ucm231538.htm.

# Fulvestrant Dosing Increased for Postmenopausal Women



Fulvestrant (Faslodex<sup>®</sup>, AstraZeneca), an estrogen-receptor antagonist, has received

FDA approval to be given in 500 mg doses to postmenopausal women with hormone receptor–positive metastatic breast cancer progressing following antiestrogen therapy.

Approval was granted based on the results of the phase III Comparison of Faslodex in Recurrent or Metastatic Breast Cancer Study (N = 736) in which patients receiving 500 mg (n = 362) demonstrated a 20% reduction in risk of disease progression compared to patients receiving the previous 250 mg dosing recommendation (n = 374). Median progression-free survival was 6.5 months for 500 mg versus 5.4 months for 250 mg (p = 0.006). Median overall survival was 25.1 months in the 500 mg arm versus 22.8 months in the 250 mg arm (p = 0.091).

The 500 mg dose should be administered in divided doses of 250 mg in 5 ml with each given over one to two minutes as intramuscular injections into each buttock on days 1, 15, 29, and monthly thereafter. In patients with moderate hepatic impairment, the dosage should be reduced to a single 250 mg injection.

Common adverse reactions include injection site pain, bone and muscle pain, hot flashes, fatigue, asthenia, nausea and vomiting, and constipation.

For more information, visit www.access data.fda.gov/drugsatfda\_docs/label /2010/021344s007s012lbl.pdf.

## SAFETY CONCERNS

#### Dose Caps Recommended for Carboplatin Use

The FDA has released recommendations for dose capping with carboplatin when estimated creatinine clearance (CrCl) is used for dosage calculations in place of actual glomerular filtration rate (GFR).

Carboplatin dosing is determined using area under the curve (AUC) calculations. AUC refers to the amount of drug exposure over time and is used with carboplatin dosing because drug elimination can reliably be estimated based on renal function. Although AUC calculations are most accurately performed with an actual GFR, the practice of using an estimated CrCl in place of GFR is common. An actual GFR would require the collection of a 24-hour urine specimen.

CrCl can be estimated using one of several formulas that measure serum creatinine along with weight, age, and gender. Unfortunately, because of how serum creatinine is measured, use of CrCl calculations can sometimes overestimate a patient's actual GFR. In such a case, unadjusted calculations of carboplatin doses using CrCl can result in overdosing with resultant toxicities.

For this reason, the FDA recommends capping GFR estimates at 125 ml per minute in patients with normal renal function.

The Calvert formula for calculating carboplatin doses is: total carboplatin dose (mg) = (target AUC) x (GFR + 25). Using the FDA capping recommendations, maximum doses would be

- Target AUC 6: Maximum carboplatin dose = 6 x 150 = 900 mg
- Target AUC 5: Maximum carboplatin dose = 5 x 150 = 750 mg
- Target AUC 4: Maximum carboplatin dose = 4 x 150 = 600 mg.

For more information, visit www.fda .gov/AboutFDA/CentersOffices/CDER/ ucm228974.htm.

## NOTEWORTHY

# Study Links Heavy Smoking to Emergence of Dementia

As reported by Rusanen, Kivipelto, Quesenberry, Zhou, and Whitmer (2010), heavy smoking, defined as greater than two packs per day during midlife, has been correlated with a greater than twofold increased incidence of dementia later in life compared to nonsmokers. Investigators examined the subsequent incidence of dementia, Alzheimer disease, and vascular dementia among 21,123 participants in a survey conducted from 1978-1985. Adjusting for other factors, with a mean follow up of 23 years, the heavy smokers were at a much higher risk for dementia (hazard ratio [HR] = 2.14; 95% confidence interval [CI], 1.65-2.78), Downloaded on 05-20-2024. Single-user license only. Copyright 2024 by the Oncology Nursing Society. For permission to post online, reprint, adept, or reuse, please email pubpermissions @ons.org. ONS reserves all rights

Rusanen, M., Kivipelto, M., Quesenberry, C.P., Jr., Zhou, J., & Whitmer, R.A. (2010). Heavy smoking in midlife and long-term risk of Alzheimer's disease and vascular dementia. Retrieved from http:// archinte.ama-assn.org/cgi/content/ short/archinternmed.2010.393

#### Wasteful Screening Examined in Cases of Advanced Cancer

In an environment of limited financial resources coupled with rising medical costs, continued evaluation of the need for and benefits of interventions used within the healthcare system is warranted.

Sima, Panageas, and Schrag (2010) sought to illuminate the extent to which screening for new cancers was being performed among fee-for-service Medicare enrollees (n = 87,736) who already had been diagnosed with advanced cancers from 1998-2005. Depending on cancer type, the median survival of these patients was 4.3–16.2 months. Despite the poor prognosis of the population, a significant number of screening examinations were performed that were unrelated to the terminal cancers being treated. For women enrollees, 9% had mammograms performed and 6% had Papanicolau examinations. For men, 15% had prostate-specific antigen tests. In addition, 2% of patients had lower gastrointestinal endoscopies performed to screen for new cancers.

Although these screening rates were lower than in a similar group of Medicare enrollees who did not have advanced cancer diagnoses (n = 87,307), the authors questioned the benefits of screening for new cancers in patients who have already been diagnosed with advanced cancer. In some cases, although the data provided by screening examinations is informative, the results have no meaningful value in terms of changing the approach to care. If this is the case, and can be anticipated as such, the question of whether the test should be performed at all should be considered by healthcare providers.

Sima, C., Panageas, K.S., & Schrag, D. (2010). Cancer screening among patients with advanced cancer. *JAMA*, 304, 1584– 1591. doi: 10:1001/jama.2010.1449

#### Correct Lifestyle Choices Could Reduce Colon Cancer Risk

A prospective cohort study in Denmark (N = 55,487) examined the effects of five modifiable lifestyle factors on the risk for developing colorectal cancer (Kirkegaard et al., 2010). The five lifestyle factors examined were smoking, alcohol consumption, physical activity, waist circumference, and dietary intake. Researchers estimated that, of the 678 colorectal cancers diagnosed among study participants at a median follow-up of 9.9 years, 23% could have been prevented through adherence to recommendations in all of the five areas examined. Participants were aged 50-64 years when initially enrolled (from 1993–1997) in the Danish Diet, Cancer, and Health Cohort Study.

Study participants were assigned a lifestyle index score (0-5) based on whether they followed specific recommendations. Each of the five categories was valued as one point on the index. For example, in the smoking category, smokers were assigned zero points (amount of smoking not specified) while nonsmokers (including former smokers) were assigned one point. For weekly alcohol intake, one point was assigned for consumption of 7 or fewer drinks for women and 14 or fewer for men. Physical activity recommendations included 30 minutes or more of moderate activity or occupational activity daily. Waist circumference points were assigned for 88 cm or less in women and 102 cm or less in men. Lastly, the point for dietary intake required adherence to all of the following for daily intake: more than 600 g of fruits and vegetables, less than 500 g of red and processed meats, more than 3 g of dietary fiber per megajoule of dietary energy, and less than 30% total caloric intake from fat.

A benefit of using a lifestyle index is that it provides a rapid and easy-to-use tool in helping people understand the impact of cumulative risk factors. In this case, higher index scores were associated with lower cancer incidence. Also, although 23% of colorectal cancers were argued to have been preventable through adherence to all five recommendations, researchers also argued that if study participants had all scored only one additional point on the index, 13% of the cancers could have been prevented.

A weakness of the index used in this study is that only 1% of participants (510 of 55,487 people) were actually able to meet all the recommendations and achieve the maximum score of five. This is mostly because only 2% were able to score a point in the dietary category. Whether a more achievable dietary recommendation also could have resulted in lower cancer incidence warrants additional study. Also, although using a five-point index provides a simple method to examine risk factors, the validity of providing equal weight to each of the categories may warrant additional examination. For example, are the risks of smoking and the risk of fewer than 30 minutes of moderate exercise daily truly equal?

Kirkegaard, H., Johnsen, N.F., Christensen, J., Frederiksen, K., Overvad, K., & Tjonneland, A. (2010). Association of adherence to lifestyle recommendations and risk of colorectal cancer: A prospective Danish cohort study. *BMJ*, 341, c5504. doi: 10.1136/bmj.c5504

Description of products does not indicate or imply endorsement by the Oncology Nursing Forum or the Oncology Nursing Society. Michael Smart, RN, BSN, OCN<sup>®</sup>, can be reached at nursemrsmart@aol.com, with copy to editor at ONFEditor@ons.org.

Digital Object Identifier: 10.1188/11.ONF.93-94

INDEX TO ADVERTISERS		
Amgen Inc C2–C4 www.amgen.com	Florida Cancer Specialists	Lilly Oncology
CancerCare 1 www.cancercare.org	Genentech	Virginia Commonwealth University School of Nursing
<b>Cedars–Sinai Samuel Oschin</b> <b>Cancer Center</b>	Leukemia & Lymphoma Society	Yale-New Haven Hospital